TEVA, US8816242098

Teva reports 44-week data: What it means for Teva Pharmaceutical Industries stock

Published on 10/22/2026 at 12:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Duvakitug remission reached 58 percent at Week 44. The November 3, 2026 results date matters for Teva Pharmaceutical Industries stock.

Pipeline data and reporting dates

Teva and Sanofi presented 44-week duvakitug data on October 20, 2026, from 130 participants.
Clinical remission reached 58 percent at the 900 mg dose versus 47 percent at 450 mg.
Teva will release third-quarter 2026 results on November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries Limited (ISIN US8816242098) and Sanofi presented 44-week duvakitug data on October 20, 2026, with clinical remission reaching 58 percent at the higher dose. The findings give Teva Pharmaceutical Industries stock a fresh pipeline milestone before the company's third-quarter results. Via Ritzau reported that the study covered ulcerative colitis and Crohn's disease.

Three milestones shape the pipeline

On October 9, 2026, Teva received U.S. approval for Weltruza, a once-monthly olanzapine injection, according to Gettex. On October 15, 2026, Barclays raised its Teva price target from USD 42.00 to USD 47.00, as reported by Markets Insider. On October 20, 2026, the duvakitug update became the latest milestone, with 130 responders entering the long-term extension study.

What does 58 percent mean?

The result came from the ulcerative colitis cohort at Week 44. Clinical remission was 58 percent among patients receiving 900 mg every four weeks, compared with 47 percent at 450 mg. Clinical response also reached 87 percent at 900 mg versus 82 percent at 450 mg, while endoscopic improvement stood at 63 percent and 59 percent, respectively. The figures are descriptive study results, so the key investor question is whether the phase 3 program can reproduce the dose response at a larger scale.

Two dates set the next checkpoints

Teva scheduled its third-quarter 2026 results release for November 3, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET, according to Teva. The company's R&D Day is scheduled for November 11, 2026, in New York City, according to Gettex.

Pipeline milestones meet reporting risk

Teva's near-term stock narrative therefore combines clinical progress with two scheduled corporate dates. The November 3 results will show how the generic and specialty-drug portfolio performed in the third quarter, while the November 11 event may add detail on research priorities and development spending.